George Hsiao Selected Research

Interleukin-10 (Interleukin 10)

5/2022	Acteoside exerts immunomodulatory effects on dendritic cells via aryl hydrocarbon receptor activation and ameliorates Th2-mediated allergic asthma by inducing Foxp3+ regulatory T cells.
1/2013	Notch ligand delta-like 4-pretreated dendritic cells alleviate allergic airway responses by enhancing IL-10 production.
1/2010	Synergistic therapeutic effects of combined adenovirus-mediated interleukin-10 and interleukin-12 gene therapy on airway inflammation in asthmatic mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

George Hsiao Research Topics

Disease

9	Ischemia 03/2019 - 09/2002
9	Brain Ischemia (Cerebral Ischemia) 09/2013 - 05/2004
9	Infarction (Infarctions) 02/2012 - 09/2002
8	Brain Injuries (Brain Injury) 09/2013 - 05/2004
7	Neuroinflammatory Diseases 04/2024 - 11/2014
7	Inflammation (Inflammations) 01/2023 - 01/2010
7	Neoplasms (Cancer) 05/2017 - 03/2010
7	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 09/2013 - 09/2005
6	Retinal Degeneration 04/2024 - 01/2017
6	Hypoxia (Hypoxemia) 01/2023 - 03/2007
6	Fibrosis (Cirrhosis) 01/2015 - 06/2009
6	Thrombosis (Thrombus) 10/2005 - 04/2003
5	Asthma (Bronchial Asthma) 05/2022 - 01/2010
4	Respiratory Hypersensitivity 05/2022 - 01/2013
4	Pulmonary Embolism 06/2013 - 04/2003
4	Reperfusion Injury 04/2013 - 09/2002
4	Thromboembolism 12/2010 - 12/2003
3	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2023 - 06/2020
3	Endotoxemia 06/2019 - 08/2002
3	Cardiovascular Diseases (Cardiovascular Disease) 06/2013 - 01/2009
3	Atherosclerosis 04/2011 - 08/2003
2	Ganglion Cysts (Ganglion) 01/2023 - 10/2015
2	Sepsis (Septicemia) 06/2019 - 06/2017
2	Uveitis 03/2019 - 01/2018
2	Fibrosarcoma 03/2018 - 02/2012
2	Lung Neoplasms (Lung Cancer) 04/2014 - 04/2012
2	Chondrosarcoma 04/2013 - 05/2011
2	Ischemic Stroke 02/2012 - 04/2011
2	Vascular Diseases (Vascular Disease) 12/2011 - 04/2006
2	Neoplasm Metastasis (Metastasis) 12/2011 - 05/2011
2	Hypertension (High Blood Pressure) 01/2009 - 01/2004
2	Hypotension (Low Blood Pressure) 01/2009 - 08/2002
2	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 07/2008 - 02/2008
2	Seizures (Absence Seizure) 09/2007 - 01/2004
2	Ventricular Fibrillation 09/2006 - 09/2002
2	Myocardial Ischemia (Ischemic Heart Diseases) 09/2006 - 09/2002
2	Shock 04/2003 - 08/2002
1	Macular Degeneration (Age-Related Maculopathy) 01/2023
1	Macular Edema 01/2023
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2023
1	Blindness (Hysterical Blindness) 01/2023

Drug/Important Bio-Agent (IBA)

11	Matrix Metalloproteinases (MMPs)IBA 06/2019 - 01/2009
9	Retinaldehyde (Retinal)IBA 02/2023 - 01/2017
9	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2015 - 03/2007
8	Free RadicalsIBA 02/2012 - 08/2002
7	CytokinesIBA 05/2022 - 01/2009
6	Neuroprotective AgentsIBA 01/2019 - 04/2006
6	Proteins (Proteins, Gene)FDA Link 01/2019 - 08/2003
6	Caspase 3 (Caspase-3)IBA 02/2012 - 03/2007
5	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 02/2012 - 04/2006
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2023 - 01/2013
4	OvalbuminIBA 05/2022 - 01/2010
4	Immunoglobulin E (IgE)IBA 05/2022 - 01/2013
4	LipopolysaccharidesIBA 06/2019 - 08/2002
4	Adenosine Diphosphate (ADP)IBA 06/2013 - 04/2003
4	Histone Deacetylase InhibitorsIBA 04/2012 - 05/2011
4	Fluorescein (Funduscein)FDA LinkGeneric 10/2005 - 05/2003
3	2,3,7,7a- tetrahydro- 3- hydroxy- 7- methyl- 2- (prop- 1- en- 1- yl)- 5H- furo(3,4- b)pyran- 5- oneIBA 02/2023 - 01/2018
3	Retinal Pigments (Pigments, Visual)IBA 01/2023 - 01/2018
3	Interleukin-10 (Interleukin 10)IBA 05/2022 - 01/2010
3	Matrix Metalloproteinase 9 (Gelatinase B)IBA 06/2019 - 06/2017
3	Histone Deacetylases (Histone Deacetylase)IBA 02/2012 - 05/2011
3	theasinensin AIBA 02/2012 - 05/2011
3	Therapeutic UsesIBA 04/2011 - 05/2004
3	SolventsIBA 04/2011 - 05/2004
3	tetramethylpyrazineIBA 03/2007 - 04/2006
3	AntioxidantsIBA 03/2007 - 04/2003
2	sodium iodateIBA 02/2023 - 01/2023
2	LipofuscinIBA 01/2023 - 04/2019
2	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 01/2023 - 05/2022
2	Interleukin-5 (Interleukin 5)IBA 05/2022 - 01/2013
2	Interleukin-13IBA 05/2022 - 01/2013
2	ethyl acetateIBA 03/2018 - 01/2017
2	Anti-Allergic Agents (Antiallergic Agents)IBA 10/2017 - 01/2016
2	imperatorinIBA 10/2017 - 01/2016
2	Coloring Agents (Dyes)IBA 10/2015 - 08/2002
2	SurvivinIBA 04/2014 - 02/2012
2	andrographolideIBA 09/2013 - 12/2011
2	Midazolam (Versed)FDA LinkGeneric 04/2013 - 03/2004
2	Plasminogen Activator Inhibitor 1IBA 04/2012 - 06/2009
2	trichostatin A (A 300)IBA 02/2012 - 05/2011
2	sesamolIBA 05/2011 - 12/2010
2	Messenger RNA (mRNA)IBA 01/2009 - 03/2007
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2009 - 08/2002
2	Amyloid beta-PeptidesIBA 07/2008 - 02/2008
2	3-nitrotyrosineIBA 03/2007 - 04/2006
2	Oxygen (Dioxygen)IBA 09/2006 - 09/2002
2	Dihydrotachysterol (AT 10)IBA 04/2006 - 09/2002
2	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 10/2005 - 06/2005
2	LycopeneIBA 10/2005 - 05/2004
2	Magnesium Sulfate (Sulfate, Magnesium)FDA LinkGeneric 01/2004 - 05/2003
1	Antiglaucoma AgentsIBA 04/2024
1	N-Methylaspartate (NMDA)IBA 04/2024
1	Advanced Glycation End ProductsIBA 01/2023
1	beta-(5-hydroxy-2-pyridyl)alanineIBA 01/2023
1	Metformin (Glucophage)FDA LinkGeneric 01/2023
1	Pyruvaldehyde (Methylglyoxal)IBA 01/2023

Therapy/Procedure

4	Therapeutics 01/2023 - 04/2011
3	Oral Administration 05/2022 - 01/2011
3	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/2017 - 01/2011